high5immunology.tv | IBD | ECCO 2023

Targeting efficacy: Discussions

ELEVATE, True North OLE

ECCO 2023

S1P modulators - a rising class of drugs

S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving

APOLLO-CD, ARTEMIS-UC

ECCO 2023

New molecules on the horizon!

S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

JAK inhibitors - small molecules to treat IBD

S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving

LIR!C, REPREVIO

ECCO 2023

A focus on surgery and post-operative maintenance

S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving

Targeting efficacy ENG

U-EXCEL, U-EXCEED, U-ENDURE U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Upadacitinib works in bionaive and bio-exposed pts in…

James Lindsay, MD

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

Latest update on JAK inhibition

Axel Dignaß, MD

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

No impact of previous therapies for Upadacitinib in…

Gerhard Rogler, MD

True North OLE

ECCO 2023

Prolonged treatment with Ozanimod recaptures remission…

Massimo Claudio Fantini, MD

U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Upadacitinib is efficacious for UC regardless of…

Séverine Vermeire, MD

ECCO 2023

Medium-term outcome of IBD patients diagnosed at…

Gerassimos Mantzaris, MD

True North, True North OLE, ELEVATE

ECCO 2023

S1P modulators in UC

Axel Dignaß, MD

EARNEST

ECCO 2023

Vedolizumab heals pouch mucosa

James Lindsay, MD

True North OLE

ECCO 2023

Long-term duration of response with ozanimod in UC

Séverine Vermeire, MD

U-ENDURE, U-EXCEED, U-EXCEL

ECCO 2023

Upadacitinib for fistulizing Crohn´s disease?

Peter Irving, MD

UNIFI

ECCO 2023

Long-term extension of ustekinumab in UC

Silvio Danese, MD

EARNEST

ECCO 2023

Mucosal healing induced by vedolizumab in chronic…

Fernando Magro, MD

Targeting efficacy Multi Language

UNIFI

ECCO 2023

Studio lungo termine di ustekinumab in UC

Silvio Danese, MD

True North OLE

ECCO 2023

Il prolungamento del trattamento con Ozanimod induce…

Massimo Claudio Fantini, MD

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

Upadacitinib: Vortherapien spielen keine Rolle mehr bei…

Gerhard Rogler, MD

True North OLE

ECCO 2023

Lang Termijn respons met ozanimod bij colitis ulcerosa

Séverine Vermeire, MD

U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Upadacitinib is efficient bij colitis ulcerosa,…

Séverine Vermeire, MD

U-EXCEL, U-EXCEED, U-ENDURE

ECCO 2023

Update zu JAK-Inhibitoren bei CED

Axel Dignaß, MD

ECCO 2023

Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που…

Gerassimos Mantzaris, MD

True North, True North OLE, ELEVATE

ECCO 2023

S1P-Modulatoren bei Colitis ulcerosa

Axel Dignaß, MD

Targeting safety: Discussions

ADVANCE, MOTIVATE, FORTIFY, GETAID, LUCENT-1 & -2

ECCO 2023

Anti-IL23 drugs: is it all the same?

M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber

GETAID

ECCO 2023

New aspects on safety of anti-TNF treatment

M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber

True North OLE, ELEVATE

ECCO 2023

S1P-modulators: a spotlight on safety

M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber

U-ACHIEVE, U-ACCOMPLISH, FINCH

ECCO 2023

Safety update on JAKis - new worries?

M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber

Targeting safety ENG

ELEVATE

ECCO 2023

Etrasimod shows fast stool frequency and rectal…

Massimo Claudio Fantini, MD

EpiPSC2

ECCO 2023

Ileostomy with better prognosis than pouch in PSC

Gerhard Rogler, MD

True North OLE

ECCO 2023

Ozanimod shows good efficacy and safety profile in UC…

Massimo Claudio Fantini, MD

ECCO 2023

Risk of IBD from early antibiotic exposure in live

David Laharie, MD

U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Positive effects of Upadacitinib on resolution of…

Gerassimos Mantzaris, MD

Targeting safety Multi Language

True North OLE

ECCO 2023

Ozanimod shows good efficacy and safety profile after…

Massimo Claudio Fantini, MD

ELEVATE

ECCO 2023

Rapido controllo del sanguinamento rettale e della…

Massimo Claudio Fantini, MD

U-ACHIEVE, U-ACCOMPLISH

ECCO 2023

Το upadacitinib επιφέρει ύφεση των κοιλιακών…

Gerassimos Mantzaris, MD

EpiPSC2

ECCO 2023

Ileostomie mit besserer Prognose als Pouch bei PSC

Gerhard Rogler, MD

ECCO 2023

Les antibiotiques dans la petite enfance augmentent le…

David Laharie, MD

Therapeutic concepts: Discussions

ECCO 2023

10 years of Tofacitinib – still more lessons to learn

J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber

REPREVIO, EpiPSC2

ECCO 2023

Practice-changing data on surgery in CD and UC

J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber

Therapeutic concepts ENG

REPREVIO

ECCO 2023

Postoperative recurrence in CD

Fernando Magro, MD

ECCO 2023

Timing of surgery in Crohn's disease

David Laharie, MD

REPREVIO

ECCO 2023

Vedolizumab for preventing postoperative reccurence of…

David Laharie, MD

epi-IIRN based

ECCO 2023

Enteral nutrition - food for thought!

Peter Irving, MD

GETECCU (EXIT)

ECCO 2023

Is it feasible to stop anti-TNF treatment in…

Gerassimos Mantzaris, MD

ELEVATE, UNIFI

ECCO 2023

New drugs on the block!

Stefan Schreiber, MD

ECCO 2023

Ileocaecal Crohn's disease - should we call the surgeon…

Piotr Eder, MD

REPREVIO

ECCO 2023

Post-surgical Crohn's disease

Stefan Schreiber, MD

epi-IIRN based

ECCO 2023

Early treatment with biologics in IBD

Peter Irving, MD

EPIC-CD

ECCO 2023

Epigenetic fingerprinting - a novel tool for precision…

Alexander Moschen, MD

epi-IIRN

ECCO 2023

Biologics in CD – is earlier better?

Iris Dotan, MD

EPIC-CD

ECCO 2023

DNA methylation predicts response to biologics in IBD

James Lindsay, MD

REPREVIO, LIR!C

ECCO 2023

Surgery in CD - resetting or not?

Matthieu Allez, MD

REPREVIO

ECCO 2023

Vedolizumab prevents postoperative recurrence in CD

Silvio Danese, MD

REPREVIO

ECCO 2023

Peri- and postoperative management of CD

Axel Dignaß, MD

EpiPSC2

ECCO 2023

Another clue for the role of the microbiome in PSC?

Iris Dotan, MD

ECCO 2023

Surgical and post-operative management in CD

Séverine Vermeire, MD

Therapeutic concepts Multi Language

EPIC-CD

ECCO 2023

Epigenetic Fingerprinting - ein neues Werkzeug für die…

Alexander Moschen, MD

ECCO 2023

Biosimilars

Stefan Schreiber, MD

GETECCU (EXIT)

ECCO 2023

Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες…

Gerassimos Mantzaris, MD

REPREVIO

ECCO 2023

Vedolizumab previene la recidiva post operatoria nei…

Silvio Danese, MD

REPREVIO

ECCO 2023

Peri- und postoperatives Management bei Morbus Crohn

Axel Dignaß, MD

ECCO 2023

Postać ileocekalna choroby Crohna - czy chirurgia ma…

Piotr Eder, MD

ECCO 2023

Résection chirurgicale précoce dans la MC

David Laharie, MD

REPREVIO, LIR!C

ECCO 2023

Résection chirurgicale au course de la maladie de…

Matthieu Allez, MD

EpiPSC2

ECCO 2023

Another clue for the role of the microbiome in PSC?

Iris Dotan, MD

ELEVATE, UNIFI

ECCO 2023

Neue Substanzen!

Stefan Schreiber, MD

REPREVIO

ECCO 2023

Chirurgischer Verlauf nach Morbus Crohn

Stefan Schreiber, MD

REPREVIO

ECCO 2023

Vedolizumab en prévention de la récidive postopératoire…

David Laharie, MD

epi-IIRN

ECCO 2023

Biologics in CD - is earlier better?

Iris Dotan, MD

ECCO 2023

Aanpak van de (post)operatieve Crohn patient

Séverine Vermeire, MD

Treatment goals: Discussions

EARNEST

ECCO 2023

Histology - a new therapeutic target in UC?

J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber

IBD-BOOST survey, LUCENT-1, LUCENT-2

ECCO 2023

Comprehensive remission - the new standard!?

J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber

Treatment goals ENG

ELEVATE

ECCO 2023

Disease clearance induced by etrasimod in UC

Fernando Magro, MD

ECCO 2023

Comprehensive Disease Control

Stefan Schreiber, MD

Treatment goals Multi Language

ECCO 2023

Comprehensive Disease Control

Stefan Schreiber, MD

Varia ENG

ECCO 2023

New opportunities from the application of artificial…

Massimo Claudio Fantini, MD

ECCO guideline

ECCO 2023

New ECCO guidelines on extraintestinal manifestations…

Piotr Eder, MD

ECCO 2023

Sequencing in IBD - congress overview

Alessandro Armuzzi, MD

ECCO 2023

Mucosal signatures suggest a mechanism for early CD…

Iris Dotan, MD

ECCO 2023

GPX4 fueling postoperative recurrence in Crohn's…

Alexander Moschen, MD

ECCO 2023

Comprehensive overview of surgery in IBD

Alessandro Armuzzi, MD

ECCO 2023

Our patients will be better off in the near future!

Fernando Gomollón, MD

Varia Multi Language

ECCO 2023

Sequencing nelle malattie infiammatorie cronicale…

Alessandro Armuzzi, MD

ECCO 2023

Una vida mejor en el futuro inmediato para nuestros…

Fernando Gomollón, MD

ECCO 2023

GPX4 fördert postoperatives Morbus Crohn Rezidiv

Alexander Moschen, MD

ECCO 2023

Nuove opportunità dall’applicazione dell’intelligenza…

Massimo Claudio Fantini, MD

ECCO 2023

Panoramica completa sulla chirurgia nelle malattie…

Alessandro Armuzzi, MD

ECCO 2023

Mucosal signatures suggest a mechanism for early CD…

Iris Dotan, MD

ECCO 2023

Nowe wytyczne ECCO dotyczące manifestacji…

Piotr Eder, MD